Ost-müük Graybug Vision, Inc. - GRAY CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.0485 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.030779% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | -0.013666% | ||||||||
| Ööpäeva tasu aeg | 22:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | 0.6337 |
| Avatud* | 0.5873 |
| Aastane muutus* | -54.47% |
| Päeva ulatus* | 0.5873 - 0.6707 |
| 52 nädala ulatus | 0.45-1.58 |
| Keskmine maht (10 päeva) | 20.42K |
| Keskmine maht (3 kuud) | 936.49K |
| Turukapitalisatsioon | 14.02M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 21.56M |
| Tulu | N/A |
| EPS | -1.72 |
| Dividendid (% kasumist) | N/A |
| Beeta | -100.00K |
| Järgmine tuluaruande kuupäev | Mar 8, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Feb 8, 2023 | 0.6707 | 0.0834 | 14.20% | 0.5873 | 0.6707 | 0.5873 |
| Feb 7, 2023 | 0.6337 | 0.0191 | 3.11% | 0.6146 | 0.6509 | 0.6018 |
| Feb 6, 2023 | 0.5926 | -0.0405 | -6.40% | 0.6331 | 0.6708 | 0.5926 |
| Feb 3, 2023 | 0.6353 | -0.0076 | -1.18% | 0.6429 | 0.6698 | 0.6315 |
| Feb 2, 2023 | 0.6706 | 0.0015 | 0.22% | 0.6691 | 0.6878 | 0.6316 |
| Feb 1, 2023 | 0.6693 | 0.0285 | 4.45% | 0.6408 | 0.6997 | 0.6326 |
| Jan 31, 2023 | 0.6519 | 0.0104 | 1.62% | 0.6415 | 0.6624 | 0.6415 |
| Jan 30, 2023 | 0.6367 | -0.0520 | -7.55% | 0.6887 | 0.6887 | 0.6218 |
| Jan 27, 2023 | 0.6511 | -0.0018 | -0.28% | 0.6529 | 0.6762 | 0.6511 |
| Jan 26, 2023 | 0.6753 | -0.0251 | -3.58% | 0.7004 | 0.7027 | 0.6538 |
| Jan 25, 2023 | 0.6898 | -0.0080 | -1.15% | 0.6978 | 0.6982 | 0.6618 |
| Jan 24, 2023 | 0.7020 | 0.0401 | 6.06% | 0.6619 | 0.7275 | 0.6619 |
| Jan 23, 2023 | 0.6803 | 0.0197 | 2.98% | 0.6606 | 0.6803 | 0.6522 |
| Jan 20, 2023 | 0.6625 | 0.0098 | 1.50% | 0.6527 | 0.6625 | 0.6527 |
| Jan 19, 2023 | 0.6616 | 0.0104 | 1.60% | 0.6512 | 0.7000 | 0.6247 |
| Jan 18, 2023 | 0.6743 | 0.0141 | 2.14% | 0.6602 | 0.7007 | 0.6602 |
| Jan 17, 2023 | 0.7095 | 0.0382 | 5.69% | 0.6713 | 0.7243 | 0.6508 |
| Jan 13, 2023 | 0.6803 | 0.0783 | 13.01% | 0.6020 | 0.6806 | 0.5943 |
| Jan 12, 2023 | 0.6172 | -0.0206 | -3.23% | 0.6378 | 0.6610 | 0.6018 |
| Jan 11, 2023 | 0.6219 | 0.0343 | 5.84% | 0.5876 | 0.6337 | 0.5826 |
Graybug Vision, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 28.57 | 37.502 | 29.832 | 35.947 |
| Müük/Üldine/admin kulud, kokku | 5.599 | 6.922 | 8.87 | 17.044 |
| Uuringud ja arendus | 22.971 | 30.58 | 20.962 | 18.903 |
| Tulud majandustegevusest | -28.57 | -37.502 | -29.832 | -35.947 |
| Intressitulud (kulu), muud tulud, neto | 0.192 | 0.393 | 0.143 | 0.126 |
| Muud, neto | 0 | 0.072 | 2.158 | 0 |
| Netotulu enne makse | -28.378 | -37.037 | -27.531 | -35.821 |
| Netotulu pärast makse | -28.378 | -37.037 | -27.531 | -35.821 |
| Netotulu enne erikulusid | -28.378 | -37.037 | -27.531 | -35.821 |
| Netotulu | -28.378 | -37.037 | -27.531 | -35.821 |
| Total Adjustments to Net Income | -4.317 | -7.055 | -7.189 | 0 |
| Arvestatav tulu, v a erikulud | -32.695 | -44.092 | -34.72 | -35.821 |
| Arvestatav tulu, koos erikuludega | -32.695 | -44.092 | -34.72 | -35.821 |
| Jaotamisele kuuluv netotulu | -32.695 | -44.092 | -34.72 | -35.821 |
| Keskmine jaotamisele kuuluv aktsia kohta | 19.1556 | 19.1556 | 21.044 | 21.1993 |
| Jaotatav EPS, v a erakorralised kulud | -1.70681 | -2.30178 | -1.64988 | -1.68973 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Jaotamisele kuuluv normaal-EPS | -1.70681 | -2.30178 | -1.64988 | -1.68973 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 11.488 | 7.741 | 8.017 | 8.701 | 10.184 |
| Müük/Üldine/admin kulud, kokku | 5.04 | 3.575 | 3.996 | 4.433 | 4.127 |
| Uuringud ja arendus | 6.448 | 4.166 | 4.021 | 4.268 | 6.057 |
| Tulud majandustegevusest | -11.488 | -7.741 | -8.017 | -8.701 | -10.184 |
| Intressitulud (kulu), muud tulud, neto | 0.039 | 0.033 | 0.028 | 0.026 | 0.035 |
| Muud, neto | 0 | 0 | 0 | 0 | |
| Netotulu enne makse | -11.449 | -7.708 | -7.989 | -8.675 | -10.149 |
| Netotulu pärast makse | -11.449 | -7.708 | -7.989 | -8.675 | -10.149 |
| Netotulu enne erikulusid | -11.449 | -7.708 | -7.989 | -8.675 | -10.149 |
| Netotulu | -11.449 | -7.708 | -7.989 | -8.675 | -10.149 |
| Total Adjustments to Net Income | 0 | 0 | 0 | 0 | |
| Arvestatav tulu, v a erikulud | -11.449 | -7.708 | -7.989 | -8.675 | -10.149 |
| Arvestatav tulu, koos erikuludega | -11.449 | -7.708 | -7.989 | -8.675 | -10.149 |
| Jaotamisele kuuluv netotulu | -11.449 | -7.708 | -7.989 | -8.675 | -10.149 |
| Keskmine jaotamisele kuuluv aktsia kohta | 21.0204 | 21.1487 | 21.2875 | 21.3376 | 21.3578 |
| Jaotatav EPS, v a erakorralised kulud | -0.54466 | -0.36447 | -0.37529 | -0.40656 | -0.47519 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.54466 | -0.36447 | -0.37529 | -0.40656 | -0.47519 |
- Aastas
- Kvartalis
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Käibevarad kokku | 13.445 | 36.271 | 99.24 | 67.078 |
| Raha ja lühiajalised investeeringud | 12.834 | 35.956 | 95.033 | 63.67 |
| Raha ja ekvivalendid | 12.834 | 15.87 | 33.418 | 13.364 |
| Lühiajalised investeeringud | 0 | 20.086 | 61.615 | 50.306 |
| Prepaid Expenses | 0.611 | 0.315 | 4.207 | 2.034 |
| Total Assets | 17.813 | 40.66 | 101.794 | 69.088 |
| Property/Plant/Equipment, Total - Net | 1.515 | 1.975 | 1.946 | 1.981 |
| Property/Plant/Equipment, Total - Gross | 1.958 | 2.714 | 3.08 | 3.634 |
| Accumulated Depreciation, Total | -0.443 | -0.739 | -1.134 | -1.653 |
| Other Long Term Assets, Total | 2.853 | 2.414 | 0.608 | 0.029 |
| Total Current Liabilities | 5.794 | 12.251 | 6.997 | 4.057 |
| Accounts Payable | 2.523 | 4.636 | 2.513 | 0.527 |
| Accrued Expenses | 2.924 | 4.377 | 3.658 | 2.582 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.347 | 3.238 | 0.826 | 0.948 |
| Total Liabilities | 5.794 | 12.251 | 7.008 | 4.065 |
| Total Long Term Debt | 0 | 0 | 0 | 0 |
| Total Equity | 12.019 | 28.409 | 94.786 | 65.023 |
| Preferred Stock - Non Redeemable, Net | 78.811 | 131.363 | 0 | 0 |
| Common Stock | 0 | 0 | 0.002 | 0.002 |
| Additional Paid-In Capital | 2.007 | 2.879 | 228.155 | 234.225 |
| Retained Earnings (Accumulated Deficit) | -68.799 | -105.836 | -133.367 | -169.188 |
| Unrealized Gain (Loss) | 0 | 0.003 | -0.004 | -0.016 |
| Total Liabilities & Shareholders’ Equity | 17.813 | 40.66 | 101.794 | 69.088 |
| Total Common Shares Outstanding | 19.1556 | 19.1556 | 20.9793 | 21.3578 |
| Other Liabilities, Total | 0.011 | 0.008 | ||
| Total Preferred Shares Outstanding | 0 | |||
| Laekumata arved, neto | 0.021 | |||
| Other Current Assets, Total | 1.353 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 88.821 | 76.051 | 74.496 | 67.078 | 58.222 |
| Raha ja lühiajalised investeeringud | 85.688 | 73.586 | 72.554 | 63.67 | 55.28 |
| Raha ja ekvivalendid | 10.589 | 7.864 | 11.452 | 13.364 | 8.36 |
| Lühiajalised investeeringud | 75.099 | 65.722 | 61.102 | 50.306 | 46.92 |
| Prepaid Expenses | 3.133 | 2.465 | 1.942 | 3.408 | 2.942 |
| Total Assets | 90.852 | 82.821 | 76.638 | 69.088 | 60.586 |
| Property/Plant/Equipment, Total - Net | 2.002 | 2.006 | 2.113 | 1.981 | 2.335 |
| Other Long Term Assets, Total | 0.029 | 0.136 | 0.029 | 0.029 | 0.029 |
| Total Current Liabilities | 6.278 | 4.141 | 4.49 | 4.057 | 4.228 |
| Accounts Payable | 1.956 | 2.101 | 2.066 | 0.527 | 0.541 |
| Accrued Expenses | 3.378 | 1.543 | 1.729 | 2.582 | 2.216 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.944 | 0.497 | 0.695 | 0.948 | 1.471 |
| Total Liabilities | 6.29 | 4.154 | 4.502 | 4.065 | 4.33 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0.012 | 0.013 | 0.012 | 0.008 | 0.102 |
| Total Equity | 84.562 | 78.667 | 72.136 | 65.023 | 56.256 |
| Common Stock | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
| Additional Paid-In Capital | 229.376 | 231.183 | 232.641 | 234.225 | 235.767 |
| Retained Earnings (Accumulated Deficit) | -144.816 | -152.524 | -160.513 | -169.188 | -179.337 |
| Unrealized Gain (Loss) | 0 | 0.006 | 0.006 | -0.016 | -0.176 |
| Total Liabilities & Shareholders’ Equity | 90.852 | 82.821 | 76.638 | 69.088 | 60.586 |
| Total Common Shares Outstanding | 21.0559 | 21.2847 | 21.3166 | 21.3578 | 21.3578 |
| Long Term Investments | 4.628 | ||||
| Preferred Stock - Non Redeemable, Net | 0 | 0 |
- Aastas
- Kvartalis
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Netotulu/algväärtus | -28.378 | -37.037 | -27.531 | -35.821 |
| Raha majandustegevusest | -28.216 | -31.215 | -32.064 | -31.5 |
| Raha majandustegevusest | 0.175 | 0.303 | 0.395 | 0.519 |
| Mittelikviidsed varad | 0.366 | 0.598 | -0.369 | 5.433 |
| Muutused tööjõus | -0.379 | 4.921 | -4.559 | -1.631 |
| Tulu investeeringutelt | -1.461 | -20.62 | -42.56 | 10.751 |
| Kapitalikulutused | -1.461 | -0.605 | -1.023 | -0.488 |
| Muud rahavood investeeringutelt, kokku | 0 | -20.015 | -41.537 | 11.239 |
| Rahavood investeeringutelt | 42.019 | 54.871 | 92.172 | 0.695 |
| Rahavoogudesse investeerimine | 0 | -0.045 | -4.16 | 0 |
| Aktsiate emiteerimine (tagasiost), neto | 42.019 | 54.916 | 96.332 | 0.695 |
| Rahaline kogumuutus | 12.342 | 3.036 | 17.548 | -20.054 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -11.449 | -19.157 | -27.146 | -35.821 | -10.149 |
| Cash From Operating Activities | -9.264 | -17.045 | -22.545 | -31.5 | -6.524 |
| Cash From Operating Activities | 0.118 | 0.247 | 0.383 | 0.519 | 0.122 |
| Non-Cash Items | 1.169 | 2.508 | 3.946 | 5.433 | 3.81 |
| Changes in Working Capital | 0.898 | -0.643 | 0.272 | -1.631 | -0.307 |
| Cash From Investing Activities | -13.657 | -9.096 | -0.035 | 10.751 | 1.52 |
| Capital Expenditures | -0.136 | -0.304 | -0.484 | -0.488 | 0 |
| Other Investing Cash Flow Items, Total | -13.521 | -8.792 | 0.449 | 11.239 | 1.52 |
| Cash From Financing Activities | 0.092 | 0.587 | 0.614 | 0.695 | 0 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0.092 | 0.587 | 0.614 | 0.695 | 0 |
| Net Change in Cash | -22.829 | -25.554 | -21.966 | -20.054 | -5.004 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Deerfield Management Company, L.P. | Hedge Fund | 24.4949 | 5281713 | 0 | 2022-11-21 | MED |
| OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 19.3083 | 4163347 | 0 | 2022-09-30 | LOW |
| AffaMed Project, Ltd | Corporation | 6.221 | 1341415 | 207819 | 2021-12-31 | |
| BML Capital Management LLC | Investment Advisor | 5.7319 | 1235943 | 1235943 | 2022-11-22 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.9466 | 419744 | -33940 | 2022-09-30 | LOW |
| First Manhattan Company | Investment Advisor | 1.3542 | 292003 | 0 | 2022-09-30 | LOW |
| CVF 2018, LLC | Corporation | 1.2651 | 272784 | -795446 | 2021-12-31 | |
| Renaissance Technologies LLC | Hedge Fund | 0.9298 | 200492 | 148392 | 2022-09-30 | HIGH |
| Guerard (Frederic) | Individual Investor | 0.7306 | 157530 | 17057 | 2022-12-01 | MED |
| BNY Mellon Asset Management | Investment Advisor | 0.4683 | 100981 | 0 | 2022-09-30 | LOW |
| Breuil (Robert S) | Individual Investor | 0.4038 | 87066 | 9772 | 2022-12-12 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3079 | 66393 | 0 | 2022-09-30 | LOW |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.2968 | 64000 | -50000 | 2022-09-30 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.2933 | 63241 | 52012 | 2022-09-30 | LOW |
| Zamiri (Parisa) | Individual Investor | 0.267 | 57577 | 6623 | 2022-12-01 | MED |
| Johnson & Johnson Innovation-JJDC, Inc. | Venture Capital | 0.2298 | 49547 | 0 | 2022-09-30 | LOW |
| Hatteras Venture Partners | Venture Capital | 0.1997 | 43064 | -1562176 | 2021-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1627 | 35073 | 0 | 2022-09-30 | LOW |
| Advisor Group, Inc | Investment Advisor | 0.0881 | 19000 | 0 | 2022-09-30 | LOW |
| Brown Advisory | Investment Advisor/Hedge Fund | 0.085 | 18333 | 1233 | 2022-09-30 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group +500000+
Kauplejad
93000+
Igakuiste aktiivsete klientide arv
$57000000+
Igakuine investeerimise maht
$31000000+
Proovige nüüd Igakuiselt välja võetud
Kauplemiskalkulaator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Kauplemise vahendustasu
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Finantsvõimendus
20:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Graybug Vision, Inc. Company profile
Ettevõttest Graybug Vision, Inc.
Graybug Vision, Inc. on kliinilise faasi biofarmatseutiline ettevõte, mis keskendub uuenduslike ravimite väljatöötamisele võrkkesta ja nägemisnärvi haiguste raviks. Ettevõtte peamine tootekandidaat GB-102 on võrkkesta haigusi põhjustava neovaskulaarse kasvu ja läbilaskvuse inhibiitori sunitiniibi mikroosakeste depotvormulatsiooni intravitreaalne süstimine. Ettevõte arendab GB-102 intravitreaalse süstena, mida manustatakse üks kord kuus kuud aastas vanusega seotud märja makulaarse degeneratsiooni (AMD) ja diabeetilise makulaödeemi (DME) raviks. Samuti kasutab ta oma tehnoloogiaid GB-103, GB-102 üks kord aastas manustatava preparaadi väljatöötamiseks diabeetilise retinopaatia (DR) raviks, ning GB-401, mis on intravitreaalselt süstitav depotvorm, mis sisaldab beeta-adrenoblokaatorite eelravimit, mille annustamisskeem on üks kord kuue kuu tagant või kauem, primaarse avatud nurga glaukoomi (POAG) raviks.
| Industry: | Bio Therapeutic Drugs |
203 Redwood Shores Parkway, Suite 620
REDWOOD CITY
CALIFORNIA 94065
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com